Biologics for Nasal Polyps

(CRSwNP Trial)

This trial tests three biologic medications—dupilumab, omalizumab, and mepolizumab—to determine which is most effective for individuals with chronic rhinosinusitis with nasal polyps (CRSwNP). These new treatment options may benefit patients who haven't found relief with other treatments like steroids. Researchers aim to discover if certain patients respond better to one of these medications based on specific health markers. This trial suits individuals living with CRSwNP, who have visible nasal polyps, and are open to trying biologic therapy. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, allowing researchers to understand its benefits for more patients.

The trial does not specify if you need to stop taking your current medications, but you must have been using an intranasal corticosteroid like mometasone for at least a month before starting. You cannot have used oral corticosteroids in the 30 days before joining.

Research has shown that the three treatments—dupilumab, mepolizumab, and omalizumab—are generally safe for people with chronic rhinosinusitis with nasal polyps (CRSwNP).

For dupilumab, studies found it to be well-tolerated, with mild side effects like eye inflammation in 2% of patients. Nosebleeds occurred more frequently, affecting 7.7% of people compared to 3% with a placebo.

Mepolizumab also maintains a strong safety record. Serious allergic reactions are rare, but awareness of them is important.

Omalizumab is another safe option, improving symptoms over the long term without major safety concerns. Some patients may experience mild side effects.

Researchers are excited about these treatments for nasal polyps because they offer new ways to manage this condition. Unlike standard treatments like corticosteroids or surgery, Dupilumab, Mepolizumab, and Omalizumab work by targeting specific pathways in the immune system. Dupilumab blocks the IL-4 and IL-13 proteins, Mepolizumab targets IL-5, and Omalizumab neutralizes IgE antibodies. These targeted approaches aim to reduce inflammation and shrink polyps more effectively, potentially offering relief for patients who haven't responded well to existing therapies.

This trial will compare three treatments—dupilumab, mepolizumab, and omalizumab—for chronic rhinosinusitis with nasal polyps (CRSwNP). Research has shown that dupilumab significantly reduces nasal polyp size, improves symptoms, and enhances quality of life, with some studies suggesting it might be the most effective option. Mepolizumab also shrinks polyps and eases nasal blockage, improving overall patient well-being. Omalizumab has improved symptoms and reduced nasal polyp scores, leading to better sinus health and quality of life. Overall, these treatments have effectively reduced symptoms and improved life for many people with CRSwNP.²⁵⁶⁷⁸